Elsevier Science, Inc.

SHERPA: Unknown

People

  1. Heller
    Heller
  2. Scher
    Scher
  3. Danila
    Danila
  4. Fleisher
    Fleisher
  5. Morris
    Morris
  6. Eastham
    Eastham
  7. Lilja
    Lilja
  8. Scardino
    Scardino
  9. Slovin
    Slovin
  10. Bochner
    Bochner

Groups

  1. Biostatistics Service (13)
  2. Department of Medicine (13)
  3. Epidemiology and Biostatistics (13)
  4. Genitourinary Oncology Service (13)
  5. Solid Tumor Oncology Division (13)
  6. Surgery (6)
  7. Urology (6)
  8. Hematologic Malignancies, Division of (3)
  9. Survivorship Research (3)
  10. GSK Faculty (2)
Search Within
  1. "Genitourinary Oncology Service"
  2. "Glenn Heller"
Formats
  1. Journal Article (13)
Groups
  1. Biostatistics Service (13)
  2. Department of Medicine (13)
  3. Epidemiology and Biostatistics (13)
  4. Genitourinary Oncology Service (13)
  5. Solid Tumor Oncology Division (13)
  6. Surgery (6)

More Groups

People
  1. Glenn Heller (13)
  2. Howard Scher (11)
  3. Daniel Danila (4)
  4. Martin Fleisher (4)
  5. Michael Morris (4)
  6. William Kelly (3)

More People

Years
  1. 2021 (1)
  2. 2017 (2)
  3. 2014 (1)
  4. 2011 (1)
  5. 2009 (1)
  6. 2007 (1)

More Years

Publications
  1. Urology (5)
  2. European Urology (3)
  3. Journal of Urology (3)
  4. Controlled Clinical Trials (1)
  5. Lancet Oncology (1)

Results (13)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Baseline testosterone levels in men with clinically localized high-risk prostate cancer treated with radical prostatectomy with or without neoadjuvant chemohormonal therapy (Alliance)
    Journal Article

    Eastham, J. A.; Heller, G.; Hillman, D. W.; Hahn, O. M.; Parsons, J. K.; Mohler, J. L.; Small, E. J.; Morris, M.
    Journal of Urology (2021)

    Fulltext@MSK | Save
  • A pilot study of a multimodal treatment paradigm to accelerate drug evaluations in early-stage metastatic prostate cancer
    Journal Article

    O'Shaughnessy, M. J.; McBride, S. M.; Vargas, H. A.; Touijer, K. A.; Morris, M. J.; Danila, D. C.; Laudone, V. P.; Bochner, B. H.; Sheinfeld, J.; Dayan, E. S.; more...
    Urology (2017)

    Fulltext@MSK | Save
  • Nuclear-specific AR-V7 protein localization is necessary to guide treatment selection in metastatic castration-resistant prostate cancer
    Journal Article

    Scher, H. I.; Graf, R. P.; Schreiber, N. A.; McLaughlin, B.; Lu, D.; Louw, J.; Danila, D. C.; Dugan, L.; Johnson, A.; Heller, G.; more...
    European Urology (2017)

    Fulltext@MSK | Save
  • Analytic and clinical validation of a prostate cancer-enhanced messenger RNA detection assay in whole blood as a prognostic biomarker for survival
    Journal Article

    Danila, D. C.; Anand, A.; Schultz, N.; Heller, G.; Wan, M.; Sung, C. C.; Dai, C.; Khanin, R.; Fleisher, M.; Lilja, H.; more...
    European Urology (2014)

    Fulltext@MSK | Save
  • TMPRSS2-ERG Status in circulating tumor cells as a predictive biomarker of sensitivity in castration-resistant prostate cancer patients treated with abiraterone acetate
    Journal Article

    Danila, D. C.; Anand, A.; Sung, C. C.; Heller, G.; Leversha, M. A.; Cao, L.; Lilja, H.; Molina, A.; Sawyers, C. L.; Fleisher, M.; more...
    European Urology (2011)

    Fulltext@MSK | Save
  • Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data
    Journal Article

    Scher, H. I.; Jia, X.; de Bono, J. S.; Fleisher, M.; Pienta, K. J.; Raghavan, D.; Heller, G.
    Lancet Oncology (2009)

    Fulltext@MSK | Save
  • A phase II trial of bortezomib and prednisone for castration resistant metastatic prostate cancer
    Journal Article

    Morris, M. J.; Kelly, W. K.; Slovin, S.; Ryan, C.; Eicher, C.; Heller, G.; Scher, H. I.
    Journal of Urology (2007)

    Fulltext@MSK | Save
  • Androgen deprivation for minimal metastatic disease: Threshold for achieving undetectable prostate-specific antigen
    Journal Article

    Beekman, K.; Morris, M.; Slovin, S.; Heller, G.; Wilton, A.; Bianco, F.; Scardino, P. T.; Scher, H. I.
    Urology (2005)

    Fulltext@MSK | Save
  • Five-year outcomes after neoadjuvant chemotherapy and conformal radiotherapy in patients with high-risk localized prostate cancer
    Journal Article

    Ryan, C. J.; Zelefsky, M. J.; Heller, G.; Regan, K.; Leibel, S. A.; Scher, H. I.; Kelly, W. K.
    Urology (2004)

    Fulltext@MSK | Save
  • Estimating survival benefit in castrate metastatic prostate cancer: Decision making in proceeding to a definitive phase III trial
    Journal Article

    Verbel, D. A.; Kelly, W. K.; Smaletz, O.; Regan, K.; Curley, T.; Heller, G.; Scher, H. I.
    Urology (2003)

    Fulltext@MSK | Save